Bioptix, Inc. (NASDAQ:BIOP) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01 Changes in Registrant’s Certifying Accountant.
notice from its independent registered public accounting firm,
GHP Horwath, P.C. (“GHP”), that GHP has chosen not to stand for
re-appointment as the Company’s auditor, and effective as of
January 13, 2017, the client-auditor relationship between the
Company and GHP Horwath, P.C. shall cease. The resignation of GHP
was not recommended by the Company’s audit committee nor was the
audit committee’s approval required.
registered public accounting firm effective January 1, 2017. The
Company is currently evaluating retention of another independent
registered public accounting firm, which will be subject to the
approval of the Company’s audit committee.
for the fiscal years ended December 31, 2015 and 2014 contained
no adverse opinion or disclaimer of opinion and was not qualified
or modified as to uncertainty, audit scope or accounting
principles.
January 13, 2017, there were no “disagreements” (as described
in Item 304(a)(1)(iv) of Regulation S-K) with GHP on any matter
of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements,
if not resolved to the satisfaction of GHP, would have caused it
to make reference in connection with its opinion to the subject
matter of the disagreement. For the fiscal years ended December
31, 2015 and 2014 and through January 13, 2017, there were no
“reportable events” within the meaning of Item 304(a)(1)(v) of
Regulation S-K.
GHP with a copy of this Form 8-K, providing GHP with the
opportunity to furnish the Company with a letter addressed to the
Securities and Exchange Commission stating whether it agrees with
the statements made by the Company herein in response to Item
304(a) of Regulation S-K as the same pertain to GHP and, if not,
stating the respect in which it does not agree. A copy of GHP’s
response is filed as Exhibit 16.1 to this Report.
|
Number
|
Exhibit
|
|
16.1
|
Letter from GHP Horwath P.C., dated January 20, 2017.
|
About Bioptix, Inc. (NASDAQ:BIOP)
Bioptix, Inc., formerly Venaxis, Inc., provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company’s line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered. Its technology is an ultra-sensitive detection platform. The design of its SPR spectrometers allows discrete areas within the sample cell to be interrogated simultaneously by use of photo-diode arrays aligned to the reflected beam from the sample cell. Its biosensors provide information on kinetic processes (association and dissociation), binding affinities, analyte concentrations and real-time molecule detection. The Company offers 404pi Enhanced SPR System, which enables real-time detection of biomolecular interactions. Bioptix, Inc. (NASDAQ:BIOP) Recent Trading Information
Bioptix, Inc. (NASDAQ:BIOP) closed its last trading session up +0.01 at 3.43 with 17,747 shares trading hands.